152 related articles for article (PubMed ID: 20510151)
1. [GSK-3beta: a central kinase for neurodegenerative diseases?].
Petit-Paitel A
Med Sci (Paris); 2010 May; 26(5):516-21. PubMed ID: 20510151
[TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.
Golpich M; Amini E; Hemmati F; Ibrahim NM; Rahmani B; Mohamed Z; Raymond AA; Dargahi L; Ghasemi R; Ahmadiani A
Pharmacol Res; 2015 Jul; 97():16-26. PubMed ID: 25829335
[TBL] [Abstract][Full Text] [Related]
3. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain.
Pei JJ; Tanaka T; Tung YC; Braak E; Iqbal K; Grundke-Iqbal I
J Neuropathol Exp Neurol; 1997 Jan; 56(1):70-8. PubMed ID: 8990130
[TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
5. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
Avila J; Wandosell F; Hernández F
Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
[TBL] [Abstract][Full Text] [Related]
6. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration.
Leroy K; Yilmaz Z; Brion JP
Neuropathol Appl Neurobiol; 2007 Feb; 33(1):43-55. PubMed ID: 17239007
[TBL] [Abstract][Full Text] [Related]
7. GSK-3 is essential in the pathogenesis of Alzheimer's disease.
Takashima A
J Alzheimers Dis; 2006; 9(3 Suppl):309-17. PubMed ID: 16914869
[TBL] [Abstract][Full Text] [Related]
8. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.
Duka T; Duka V; Joyce JN; Sidhu A
FASEB J; 2009 Sep; 23(9):2820-30. PubMed ID: 19369384
[TBL] [Abstract][Full Text] [Related]
9. Probing novel 1-aza-9-oxafluorenes as selective GSK-3beta inhibitors.
Voigt B; Krug M; Schächtele C; Totzke F; Hilgeroth A
ChemMedChem; 2008 Jan; 3(1):120-6. PubMed ID: 18000938
[TBL] [Abstract][Full Text] [Related]
10. [Alzheimer's disease: cellular and molecular aspects].
Octave JN; Pierrot N
Bull Acad Natl Med; 2008 Feb; 192(2):323-31; discussion 331-2. PubMed ID: 18819686
[TBL] [Abstract][Full Text] [Related]
11. GSK-3 inhibitors for Alzheimer's disease.
Avila J; Hernández F
Expert Rev Neurother; 2007 Nov; 7(11):1527-33. PubMed ID: 17997701
[TBL] [Abstract][Full Text] [Related]
12. Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease.
Kozikowski AP; Gaisina IN; Petukhov PA; Sridhar J; King LT; Blond SY; Duka T; Rusnak M; Sidhu A
ChemMedChem; 2006 Feb; 1(2):256-66. PubMed ID: 16892358
[TBL] [Abstract][Full Text] [Related]
13. Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576.
Chauhan NB; Siegel GJ; Feinstein DL
Neuropharmacology; 2005 Jan; 48(1):93-104. PubMed ID: 15617731
[TBL] [Abstract][Full Text] [Related]
14. Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.
Hurtado DE; Molina-Porcel L; Carroll JC; Macdonald C; Aboagye AK; Trojanowski JQ; Lee VM
J Neurosci; 2012 May; 32(21):7392-402. PubMed ID: 22623685
[TBL] [Abstract][Full Text] [Related]
15. Role of protein kinase B in Alzheimer's neurofibrillary pathology.
Pei JJ; Khatoon S; An WL; Nordlinder M; Tanaka T; Braak H; Tsujio I; Takeda M; Alafuzoff I; Winblad B; Cowburn RF; Grundke-Iqbal I; Iqbal K
Acta Neuropathol; 2003 Apr; 105(4):381-92. PubMed ID: 12624792
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometry-based method to analyze the change in Tau phosphorylation in a hGSK-3beta and hTau over-expressing EcR-293 cell line.
Kurko D; Boros A; Dezso P; Urbányi Z; Sárvári M; Nagy J; Szombathelyi Z; Szendrei GI
Neurochem Int; 2006 Apr; 48(5):374-82. PubMed ID: 16420965
[TBL] [Abstract][Full Text] [Related]
17. New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease.
Medina M; Avila J
Expert Opin Ther Targets; 2014 Jan; 18(1):69-77. PubMed ID: 24099155
[TBL] [Abstract][Full Text] [Related]
18. Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease.
Maqbool M; Mobashir M; Hoda N
Eur J Med Chem; 2016 Jan; 107():63-81. PubMed ID: 26562543
[TBL] [Abstract][Full Text] [Related]
19. Personalized Medicine and Resurrected Hopes for the Management of Alzheimer's Disease: A Modular Approach Based on GSK-3β Inhibitors.
Arafa RK; Elghazawy NH
Adv Exp Med Biol; 2017; 1007():199-224. PubMed ID: 28840559
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.
Muntané G; Dalfó E; Martinez A; Ferrer I
Neuroscience; 2008 Apr; 152(4):913-23. PubMed ID: 18343584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
